Ceramides-Emerging Biomarkers of Lipotoxicity in Obesity, Diabetes, Cardiovascular Diseases, and Inflammation

Overview

Journal Diseases

Date 2024 Sep 27

PMID 39329864

Authors

Ginka Delcheva

Katya Stefanova

Teodora Stankova

Affiliations

Soon will be listed here.

Abstract

Abnormalities in lipid homeostasis have been associated with many human diseases, and the interrelation between lipotoxicity and cellular dysfunction has received significant attention in the past two decades. Ceramides (Cers) are bioactive lipid molecules that serve as precursors of all complex sphingolipids. Besides their function as structural components in cell and mitochondrial membranes, Cers play a significant role as key mediators in cell metabolism and are involved in numerous cellular processes, such as proliferation, differentiation, inflammation, and induction of apoptosis. The accumulation of various ceramides in tissues causes metabolic and cellular disturbances. Recent studies suggest that Cer lipotoxicity has an important role in obesity, metabolic syndrome, type 2 diabetes, atherosclerosis, and cardiovascular diseases (CVDs). In humans, elevated plasma ceramide levels are associated with insulin resistance and impaired cardiovascular and metabolic health. In this review, we summarize the role of ceramides as key mediators of lipotoxicity in obesity, diabetes, cardiovascular diseases, and inflammation and their potential as a promising diagnostic tool.

Citing Articles

Dairy Wastewaters to Promote Mixotrophic Metabolism in () : Effect on Biomass Composition, Phycocyanin Content, and Fatty Acid Methyl Ester Profile.

Baraldi L, Usai L, Torre S, Fais G, Casula M, Dessi D Life (Basel). 2025; 15(2).

PMID: 40003594 PMC: 11856459. DOI: 10.3390/life15020184.

References

Nixon G . Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol. 2009; 158(4):982-93. PMC: 2785521. DOI: 10.1111/j.1476-5381.2009.00281.x. View

Ding S, Li G, Fu T, Zhang T, Lu X, Li N . Ceramides and mitochondrial homeostasis. Cell Signal. 2024; 117:111099. DOI: 10.1016/j.cellsig.2024.111099. View

Hammerschmidt P, Bruning J . Contribution of specific ceramides to obesity-associated metabolic diseases. Cell Mol Life Sci. 2022; 79(8):395. PMC: 9252958. DOI: 10.1007/s00018-022-04401-3. View

Choi R, Tatum S, Symons J, Summers S, Holland W . Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021; 18(10):701-711. PMC: 8978615. DOI: 10.1038/s41569-021-00536-1. View

Gaggini M, Ndreu R, Michelucci E, Rocchiccioli S, Vassalle C . Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease. Int J Mol Sci. 2022; 23(5). PMC: 8911014. DOI: 10.3390/ijms23052719. View

Hajduch E, Balendran A, Batty I, Litherland G, Blair A, Downes C . Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia. 2001; 44(2):173-83. DOI: 10.1007/s001250051596. View

Dusing P, Heinrich N, Al-Kassou B, Gutbrod K, Dormann P, Nickenig G . Analysis of circulating ceramides and hexosylceramides in patients with coronary artery disease and type II diabetes mellitus. BMC Cardiovasc Disord. 2023; 23(1):454. PMC: 10498560. DOI: 10.1186/s12872-023-03454-x. View

Hildebrandt X, Ibrahim M, Peltzer N . Cell death and inflammation during obesity: "Know my methods, WAT(son)". Cell Death Differ. 2022; 30(2):279-292. PMC: 9520110. DOI: 10.1038/s41418-022-01062-4. View

Brady E, Cao T, Moss A, Athithan L, Ayton S, Redman E . Circulating sphingolipids and relationship to cardiac remodelling before and following a low-energy diet in asymptomatic Type 2 Diabetes. BMC Cardiovasc Disord. 2024; 24(1):25. PMC: 10765891. DOI: 10.1186/s12872-023-03623-y. View

10.

Havulinna A, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K . Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. Arterioscler Thromb Vasc Biol. 2016; 36(12):2424-2430. DOI: 10.1161/ATVBAHA.116.307497. View

11.

Yin W, Li F, Tan X, Wang H, Jiang W, Wang X . Plasma Ceramides and Cardiovascular Events in Hypertensive Patients at High Cardiovascular Risk. Am J Hypertens. 2021; 34(11):1209-1216. DOI: 10.1093/ajh/hpab105. View

12.

Gaggini M, Sabatino L, Vassalle C . Conventional and innovative methods to assess oxidative stress biomarkers in the clinical cardiovascular setting. Biotechniques. 2020; 68(4):223-231. DOI: 10.2144/btn-2019-0138. View

13.

Sokolowska E, Blachnio-Zabielska A . The Role of Ceramides in Insulin Resistance. Front Endocrinol (Lausanne). 2019; 10:577. PMC: 6712072. DOI: 10.3389/fendo.2019.00577. View

14.

Lee Y, Hirose H, Ohneda M, Johnson J, McGarry J, Unger R . Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 1994; 91(23):10878-82. PMC: 45129. DOI: 10.1073/pnas.91.23.10878. View

15.

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D . Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016; 37(25):1967-76. PMC: 4929378. DOI: 10.1093/eurheartj/ehw148. View

16.

Juszczak F, Pierre L, Decarnoncle M, Jadot I, Martin B, Botton O . Sex differences in obesity-induced renal lipid accumulation revealed by lipidomics: a role of adiponectin/AMPK axis. Biol Sex Differ. 2023; 14(1):63. PMC: 10537536. DOI: 10.1186/s13293-023-00543-6. View

17.

Guo J, Feng J, Qu H, Xu H, Zhou H . Potential Drug Targets for Ceramide Metabolism in Cardiovascular Disease. J Cardiovasc Dev Dis. 2022; 9(12). PMC: 9782850. DOI: 10.3390/jcdd9120434. View

18.

Bikman B, Summers S . Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest. 2011; 121(11):4222-30. PMC: 3204836. DOI: 10.1172/JCI57144. View

19.

Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano T . The Heart of the World. Glob Heart. 2024; 19(1):11. PMC: 10809869. DOI: 10.5334/gh.1288. View

20.

Hilvo M, Vasile V, Donato L, Hurme R, Laaksonen R . Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. Front Endocrinol (Lausanne). 2020; 11:570628. PMC: 7550651. DOI: 10.3389/fendo.2020.570628. View